Dr Tom Brodnicki is Chief Scientific and Operating Officer of Effica Biolabs, a CRO that provides bespoke preclinical services to help biotech/pharma and academic groups test candidate drugs, cells and devices for type 1 diabetes and accelerate their path to the clinic. He also has a leading role in research within the Immunology & Diabetes Unit at St Vincent’s Institute, investigating how genetic and transcriptomic variation shapes immune cell responses that drive autoimmune disease and affect drug responses.